BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

EXELA PHARMA SCIENCES — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

EXELA PHARMA SCIENCES

via BROYDRICK & ASSOCIATES

3rd Quarter (July 1 - Sep 30) · 2021Posted Oct 19, 2021Filing document ↗LDA record ↗

Income$10Kfee reported

Client

Name: EXELA PHARMA SCIENCES
Description: Injectable and ophthalmic pharmaceutical products.
Location: North Carolina · United States of America

Registrant

Firm: BROYDRICK & ASSOCIATES
Description: Government relations and lobbying.
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Pharmacy
Drug shortages and FDA approval, USTR acceptance.
LobbyistsWILLIAM B BROYDRICK
TargetedSENATE · HOUSE OF REPRESENTATIVES · Food & Drug Administration (FDA)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.